890 results about "Lymph" patented technology

The invention discloses construction and application of an oral gel drug delivery system based on a yeast microcapsule, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, the drug delivery system is composed of budesonide nanoparticles, the yeast microcapsule and gel, budesonide nanoparticles are prepared from budesonide and a polylactic acid-glycolic acid copolymer through a water-in-oil emulsification evaporation technology, yeast cell wall microcapsules are formed after content of yeast powder is removed, and the budesonide-loaded yeast microcapsules are prepared from the yeast microcapsules and the budesonide nanoparticles through stirring, ultrasonic treatment and freeze drying methods. The yeast cell wall microcapsule without contents is used as a carrier, so that the medicine is protected from being degraded by gastric acid, and the intestinal immune response is regulated by targeting intestinal related lymphatic tissues (GALT). The gel prepared by combining pectin can prolong the residence time of the drug in the intestinal tract, realizes continuous release, reduces the whole-body side effect of budesonide, and improves the treatment efficiency.

The invention relates to a method for detecting a B cell subset in a lymphatic tissue, a kit comprising a quantum dot-antibody CD19 conjugate, a quantum dot-antibody CD138 conjugate and a quantum dot-antibody CD1d conjugate is used for dyeing a lymphatic tissue section, and different antibodies are marked by quantum dots with different colors, so that the B cell subset in the lymphatic tissue section can be detected, and the B cell subset in the lymphatic tissue section can be detected. Content and positions of plasma cells and regulating B cells are confirmed, so that biological behaviors of the plasma cells and regulating B cells can be determined conveniently. According to the method, the existing multi-color immunofluorescence technology is improved, a secondary antibody dyeing link is omitted by using a quantum dot carrying antibody method, a direct method is adopted for marking, the advantages of quantum dots are exerted, the experiment time is saved, and the efficiency is improved.

The invention relates to an application of galuteolin-sensitized cis-platinum in preparation of a medicine for treating esophageal squamous cell carcinoma. It is found that the galuteolin can block the progress of esophageal squamous carcinoma cells in multiple links including apoptosis induction, growth and invasion inhibition and the like, the galuteolin can also significantly enhance inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells in a mouse model, and the galuteolin and the cis-platinum have a significant synergistic effect.

The invention relates to the field of image analysis, in particular to a colon cancer lymph node metastasis risk prediction method and system based on image analysis. The method comprises the following steps: acquiring a pathological section scanning image, carrying out layer-by-layer downsampling and feature reconstruction, and generating pathological section topological features; carrying out adaptive clustering analysis and multi-parameter fusion evaluation on the basis of the pathological section topological features to obtain independent migration evaluation values of individual tumor cells; performing tumor metastasis branch analysis according to the independent migration evaluation value, and constructing a metastasis branch path distribution diagram; extracting an immunohistochemical staining image of a patient to obtain immune cell space distribution data; and performing multi-region lymphatic metastasis simulation and metastasis risk situation prediction based on the immune cell spatial distribution data and the metastasis branch path distribution diagram to obtain a final metastasis risk assessment result. According to the method, the lymph node metastasis risk is accurately and efficiently analyzed, and the credibility of a pathological analysis result is improved.

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

The invention provides an application of a T lymphatic activation related cytokine as a biomarker in prediction of children immune globulin non-reactive Kawasaki disease. The team finds that in patients of an IVIG sensitive group and an IVIG non-response group, differences of expression levels of IL-6 and IL-17 before and after treatment have statistical significance; meanwhile, ROC curve analysis shows that IL-6 and IL-17 serve as early warning signals, and the prediction efficiency of the IVIG-unreacted Kawasaki disease is remarkably superior to that of existing prediction factors. Particularly, the levels of IL-6 and IL-17 are re-evaluated after initial treatment, so that the early prediction accuracy of the IVIG unresponsive Kawasaki disease can be further improved. By introducing IL-6 and IL-17 as novel biomarkers, early accurate prediction of the IVIG unresponsive Kawasaki disease is realized. Compared with the prior art, the method can provide a quicker and more accurate risk assessment basis for clinicians, so that early recognition of high-risk patients, optimization of subsequent treatment schemes and reduction of serious complications are facilitated, and a new thought and direction are provided for clinical diagnosis and treatment.

The invention belongs to the field of biological medicine, and discloses application of a product related to a gliolymphatic system to preparation of a product for diagnosing or treating sepsis encephalopathy. It is found for the first time that the gliolymphatic system can effectively diagnose sepsis encephalopathy, cognitive impairment, neuroinflammation and astrocyte A1 type activation severity of the sepsis encephalopathy. The invention also finds that promotion and improvement of gliolymphatic system reflux are effective therapeutic targets for sepsis encephalopathy. The invention provides a new thought for preparing diagnosis products and treatment products (such as adenovirus products capable of coding and synthesizing vascular endothelial growth factor C) of sepsis encephalopathy, and has a wide application prospect.

The invention is applicable to the technical field of biological medicines, and provides application of Paquinimod in preparation of a medicine for treating secondary lymphedema. According to the application, the S100A8 / A9 dimer small-molecule inhibitor Paquinimod is used for treating mice with lymphedema, and a result shows that the Paquinimod can be used for remarkably inhibiting secretion of inflammatory factors of the model mice, effectively relieving the edema condition and inhibiting activation of an S100A8 / A9-TLR4-CCL2 signal channel. Therefore, the inhibitor Paquinimod of the S100A8 / A9-TLR4 signal channel is applied to preparation of the medicine for treating the secondary lymphedema (SL), a new thought and a new method are developed for treatment of the SL, and the problem that the SL lacks an effective treatment means is effectively solved.

The invention relates to a lymphatic system regulation and control method and application. A lymphatic system modulator and / or a physical stimulus is provided to the subject to modulate the lymphatic system. The method provided by the invention is applied to organisms and can effectively improve the circulation function of a lymphatic-like system in a biological brain, so that an effective strategy is provided for treatment of brain function diseases.

The invention relates to the technical field of medical data management and analysis, in particular to a lymphedema treatment monitoring data management method and system. Comprising the following steps: synchronously acquiring bioelectrical impedance, tissue thermodynamic characteristics and subcutaneous tissue morphological data of a patient through multi-modal data acquisition equipment; transmitting the data to a cloud processing platform in a distributed manner, and generating a three-dimensional illness state assessment map containing edema quantitative indexes through a machine learning assessment model; generating a personalized treatment strategy adjustment scheme with a confidence score based on dynamic comparison between the current evaluation map and historical data; feeding back the evaluation map and the adjustment scheme to the medical staff through the interaction terminal, and receiving a clinical correction instruction; according to the method, on the premise of strictly protecting patient data privacy, cross-mechanism multi-modal knowledge sharing can be realized, and the contradiction between a data island and a model effect is solved.

The embodiment of the invention discloses a lymphedema identification method and device applied to breast cancer postoperation. A specific embodiment of the method comprises the following steps: constructing an upper limb three-dimensional model according to an acquired upper limb image sequence; performing upper limb state recognition according to the upper limb image sequence and the upper limb three-dimensional model to generate upper limb state information; according to the upper limb state information, the collected chief complaint information, breast cancer operation treatment information corresponding to the to-be-recognized object and a pre-trained lymphedema recognition model, lymphedema recognition information is generated; and in response to the lymphedema identification information, representing that the to-be-identified object has lymphedema, and according to the lymphedema identification information, generating rehabilitation suggestion information corresponding to the to-be-identified object. By means of the implementation mode, the patient after the breast cancer operation can find out the lymphedema of the patient as soon as possible, and the patient can be prevented and treated as soon as possible when the lymphedema occurs.

The invention discloses a breast cancer postoperative shoulder joint braking device, belongs to the technical field of medical auxiliary tools, and aims to solve the problem that lymphedema is easily caused due to the fact that a breast cancer postoperative braking device cannot adjust the lifting height of a lower arm on the affected side in the prior art. Comprising an upper arm supporting plate, a forearm supporting plate, an angle adjusting assembly and a fixing belt, the upper arm supporting plate comprises a first supporting part and a first rotating connecting part, and the first supporting part is used for placing the upper arm of a patient; the forearm supporting plate comprises a second supporting part and a second rotary connecting part, and the second supporting part is used for placing the forearm of the patient; the angle adjusting assembly comprises a first gear, a second gear and a rocking handle, the first gear is rotatably connected to the first rotary connecting part, the second gear is fixed to the second rotary connecting part, and the first gear is meshed with the second gear; a rocking handle is arranged on the surface of the first gear; the two ends of the fixing band are detachably and fixedly connected to the outer wall face of the forearm supporting plate and used for being bound to the shoulder on the opposite side of the shoulder on the affected side.

The invention relates to application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma. It is found that chrysin can sensitize the growth inhibition effect, invasion inhibition effect and apoptosis induction effect of cis-platinum-mediated esophageal squamous carcinoma cells in a dose-dependent manner, and can effectively enhance the growth inhibition and apoptosis promotion effect of cis-platinum-mediated tumors to inhibit the increase of the tumor volume. The inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells is remarkably enhanced, and a synergistic anti-cancer effect is generated through combination of cis-platinum and cis-platinum.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The disclosure relates to devices and methods for the treatment of edema, which devices use a restrictor for flow compensation. Devices and methods of the invention further use a flow-restrictor in the circulatory system, upstream of an intravascular pump, to balance pressure changes induced by the pump and to compensate for downstream flow. The device may be provided as an indwelling, intravascular catheter with a mechanical pump such as an impeller and a selectively deployable restrictor such as an inflatable balloon. Congestive heart failure or edema is treated by\operating the pump in an innominate vein and using the restrictor for flow compensation, to restrict the upstream flow and thus amplify or maintain pressure reduction at the lymphatic outlet.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

The utility model provides an ankle pump movement device for preventing lower limb deep venous thrombosis, which relates to the technical field of medical training and comprises a base and a pedal, a rotating shaft for controlling the pedal to rotate is arranged outside the base, and the pedal is arranged outside a support frame. A fixed adjusting mechanism used for adjusting the axis position of the supporting frame is arranged outside the rotating shaft, and the fixed adjusting mechanism comprises fixed plates symmetrically arranged outside the rotating shaft; through the arrangement of the gravity block, the control push plate, the control spring and the toe plate, a user can normally step on the foot when stepping on the foot. When the user hooks the feet, the toe plate can assist in completing upward hooking of tiptoes at the maximum angle, tibia anterior muscles can contract and become short, and triceps calf muscles can relax and extend, muscle contraction and relaxation are alternately carried out, blood and lymph backflow can be squeezed like a pump, and meanwhile, when the muscles are relaxed, the user can feel comfortable when hooking the feet. And fresh blood can be supplemented, so that a better exercise effect is achieved.

The invention provides a remote monitoring method and system for lymphedema pressure treatment of a patient at home, and relates to the field of lymphedema pressure treatment. The remote monitoring system based on the lymphedema pressure treatment of the household patient comprises an intelligent tubular bandage, a multifunctional sensor module is embedded in the inner layer of the intelligent tubular bandage, and the intelligent tubular bandage comprises an ultrathin pressure sensor, a human body composition sensor, a skin texture monitor, a temperature sensor and a humidity sensor and is used for comprehensively monitoring various physiological parameters wound on limbs of the patient. Through the design of the multifunctional sensor module and the flexible circuit embedded in the intelligent tubular bandage, the accuracy and sensitivity of monitoring physiological parameters of a patient by the system are remarkably improved, the flexible circuit can be adaptively adjusted to adapt to the shape and movement of limbs of the patient, measurement errors caused by movement of the bandage or movement of the patient are reduced, and the measurement accuracy is improved. And the stability of data acquisition is ensured.

The treatment system includes a limb sleeve containing a heating subsystem, a pressure subsystem, and a vibration subsystem. The heating subsystem provides controlled cyclic heating to the limb, leading to dilation of the microvasculature and improved blood flow to nerve receptors. The pressure subsystem provides progressively staged, cyclic pressure to the limb, thereby improving blood circulation to the limb, reducing edema buildup, and flushing waste out the lymphatic system. The vibration subsystem provides controlled vibrotactile sensation to the limb to promote neuronal stimulation and decrease pain sensation. The treatment system allows for a multi-faceted approach in disease stabilization and assistive, personalized treatment for peripheral neuropathy.

The invention belongs to the technical field of biological detection, and particularly relates to a prediction model for predicting prognosis after neoadjuvant immunotherapy of non-small cell lung cancer (NSCLC) through metastatic lymph nodes (mLN) and a construction method of the prediction model. According to the invention, a plurality of spatial high-throughput sequencing bioinformatics technologies are utilized to analyze a key immune cell subset, an immune microenvironment topological feature structure and a three-level lymphosome related functional cell subset of mLN after new adjuvant immunotherapy; the prediction model for predicting prognosis after neoadjuvant immunotherapy aiming at NSCLC through metastatic lymph nodes and the construction method of the prediction model are more in line with post-treatment immune microenvironment spatial histological characteristic changes, and compared with a previous transcriptome sequencing method without spatial information, the prediction model has the advantages that the prediction model is more efficient and efficient; the change of a space tumor immune microenvironment after immunotherapy is more accurately represented, and the prognosis after NSCLC neoadjuvant immunotherapy can be more accurately predicted through cell targets really influencing the immune curative effect.

The invention relates to a three-level lymphoid structure model and a preparation method thereof, and belongs to the technical field of cell biology. The method for preparing the three-stage lymphoid structure model comprises the following steps: S1, inducing and activating peripheral blood mononuclear cells by using an extracellular matrix to obtain activated peripheral blood mononuclear cells; s2, the peripheral blood mononuclear cells and the mesenchymal stem cells activated in the step S1 are coated with hydrogel, and hydrogel microspheres are obtained; and S3, culturing T cells and B cells by using the hydrogel microspheres obtained in the step S2 to obtain the three-stage lymphatic structure. The three-level lymphoid structure model obtained by the invention maintains long-term stability in vitro, the form is normal, and the activity of T cells and B cells is strong. The method can be used for dynamically observing the three-level lymphoid structure in the subsequent research immunotherapy and drug screening process, is used for high-throughput experiments, effectively improves the efficiency of drug screening experiments, and is high in accuracy.

The invention discloses a lymphedema home supervision method and related equipment. The method comprises the steps that the circumference data of an affected limb of a patient are obtained through a monitoring ring, the monitoring ring comprises a wrist strap with the adjustable length, and the wrist strap can stretch out or retract in the adjustable position; under the condition that it is determined that the monitoring ring retracts to the proper length, the circumference diameter and biological resistivity data of the affected limb of the patient at the wearing position of the monitoring ring are obtained; and analyzing the lymphedema condition of the affected limb of the patient based on the circumference data and the biological resistivity data of the affected limb of the patient. The method can solve the problems that although a current common home monitoring method such as a flexible rule for measuring the limb circumference is convenient, the influence of human factors is large, and high precision is difficult to guarantee. And although a clinically used body fluid composition monitoring instrument is accurate, the equipment is expensive and is not suitable for being used by the patient at home, so that the patient cannot conveniently and stably carry out self-monitoring for a long time at home.

The invention discloses an intelligent classification and recognition method for ear-nose-throat lesion images, and relates to the technical field of image recognition, and the method comprises the steps: synchronously collecting a nasopharynx white light image and an i-Scan image, screening an image meeting a quality standard, carrying out the correlation of pathology and grading labeling, and constructing a data set containing a multi-center case; the white light image and the i-Scan image are subjected to denoising processing, key mark points are extracted, image registration is completed, a mucous membrane surface area, a submucous membrane blood vessel area and a lymphatic tissue enrichment area are divided through semantic segmentation, and feature enhancement is carried out on different areas; extracting morphological features and textural features from the enhanced image, calculating feature importance weights and fusing the feature importance weights into low-dimensional feature vectors; the benign and malignant dichotomy model and the pathological type multi-classification model are respectively constructed, and classification results are output in combination with a doctor diagnosis rule base and verification indexes, so that the accuracy and clinical practicability of ear-nose-throat lesion diagnosis are remarkably improved.

The invention discloses a living blood vessel and lymph multi-parameter quantitative photoacoustic microscopic imaging system which comprises a high repetition frequency laser source, a photoacoustic scanning probe and a molecular imaging device. Through the cooperation of the multi-wavelength fast switching laser and the high-speed scanning probe, synchronous, dynamic and quantitative imaging of vascular function parameters and lymph concentration in a living tissue microenvironment is realized. The system has a video-level imaging rate and can capture a rapid biological process; through coaxial design of dispersion correction and a photoacoustic focus, high spatial resolution and high signal-to-noise ratio of a multispectral image are guaranteed; and the compact probe design realizes large-range scanning. The technology provides a powerful in-vivo visualization tool for research on life science problems such as tumor evolution and drug metabolism.

The invention provides a piezoelectric microneedle preparation for non-invasive and non-drug treatment of lymphedema as well as a preparation method and application of the piezoelectric microneedle preparation. The piezoelectric microneedle preparation comprises a substrate with piezoelectric performance and a microneedle array which is distributed on one side of the substrate and has conductive performance. Wherein the substrate is prepared from a piezoelectric material and is subjected to polarization treatment; the microneedle array is prepared from a degradable material or a conductive polymer material, the degradable microneedle array is loaded with or coated with a conductive material, and the conductive polymer material can generate local charges. The micro-needle is high in penetration strength and small in invasion, and the pain of a patient is reduced; meanwhile, complex wire and electrode connection is not needed, so that the infection problem caused by a traditional power supply system is avoided; therefore, the cost is low, and long-term storage is facilitated; and a larger wound is not caused, so that the pain of a patient is relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a BACE2 inhibitor and a composition in preparation of a medicine for treating arteriovenous fistula stenosis after renal failure. The invention provides an application of a BACE2 inhibitor and a composition thereof in preparation of drugs for prevention, adjuvant therapy or treatment of arteriovenous fistula stenosis after renal failure. According to the medicine, by reducing the expression level of BACE2 and reducing the content of soluble sVEGFR3, construction of a lymphatic network on the surface of arteriovenous fistula after renal failure is promoted, inflammation infiltration is relieved or neointima production is relieved, and the effects of prevention, adjuvant therapy or treatment of arteriovenous fistula stenosis after renal failure are achieved. The BACE2 inhibitor composition provided by the invention is simple in preparation method, can play a role in slow release of the BACE2 inhibitor, and is an effective intervention means for preventing and treating arteriovenous fistula stenosis after renal failure.

The invention provides an external traditional Chinese medicine preparation for lymphedema, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from astragalus membranaceus, cassia twig, poria cocos, akebiaquinata, ligusticum wallichii, salvia miltiorrhiza, radix bupleuri, scutellaria baicalensis, lalang grass rhizome and herba lycopi, and all the medicines are combined to jointly achieve the effects of tonifying qi, activating blood, inducing diuresis, soothing liver-qi stagnation and clearing away heat and toxic materials. The traditional Chinese medicine preparation has obvious edema eliminating and anti-inflammatory effects on lymphedema model mice, and the treatment effect is remarkable. Meanwhile, the traditional Chinese medicine preparation for external treatment of lymphedema in traditional Chinese medicine provided by the invention can remarkably improve clinical symptoms of a patient, relieve pain of the patient, help the patient recover a functional state, reduce the level of inflammatory factors, promote edema absorption of the patient and remarkably relieve the lymphedema condition of an affected limb, and the curative effect is remarkable.

This invention discloses a method for constructing a biological model of tertiary lymphoid structures, which can rapidly and efficiently induce the generation of in situ TLS, without relying on specific tissues or organs, and without the need for complex and expensive preparation processes such as cell editing and transgenic mice. It can generate stable, mature, and long-lasting TLS structures within 2 to 3 weeks, and has the characteristics of short cycle, low cost, simple operation, reproducibility, safety and effectiveness.

The invention provides application of combination of tageteoside and difacitinib or ponatinib to blocking of esophageal squamous cell carcinoma progression. The tageteoside is combined with an FAK inhibitor defacitinib or an Src family kinase inhibitor ponatinib, so that the metastasis of esophageal squamous carcinoma, especially lymphatic metastasis, can be inhibited, the growth of primary focus and metastatic focus esophageal squamous carcinoma cells can be inhibited, and a synergistic anti-cancer effect is achieved.